Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
CA 2406220 C · Owner: Fox, Judith A. · Inventors: Brettman, Lee R.; Allison, David Edward; Fox, Judith A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues comprising administering to said , human an effective amount of a human or humanized immunoglobulin or antigenbinding fragment thereof having binding specificity for .alpha.4.beta.7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 13, 2001 and granted February 12, 2019. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 13, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 13, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.